GlaxoSmithKline UK Ltd.

GSK and Oxford University Collaborate on Cancer Vaccines

GSK and the University of Oxford have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The program, in which GSK plans to invest up to £50 million over a minimum of three years, will conduct translational research, exploring precancer biology to generate key insights on how cancer develops in humans that could inform future development of cancer vaccines.

GSK Acquires Lupus Drug Candidate from Chimagen Biosciences

GlaxoSmithKline (GSK) agreed to acquire a clinical-stage drug from Chimagen Biosciences, a privately held Chinese biotechnology company. CMG1A46 is a dual CD19 and CD20-targeted T cell-engager (TCE), which GSK plans to develop and commercialize with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases.

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

GSK and Zhifei Co-Promote Shingles Vaccine in China

GSK has struck a deal with Chongqing Zhifei Biological Products to promote the British group's shingles vaccine, Shingrix, in China for an initial three-year period. Starting on Jan.1, 2024, Zhifei will have exclusive rights to import and distribute Shingrix in China through its service network of more than 30,000 vaccination points across the country.

Rx-360 Continues to Intensify Work in 2011